Famon Awal Bros Sedaya (PRAY) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Famon Awal Bros Sedaya stock IDR 332, price IDR 700, that is 52.6% below the price, quality 46 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
48‑month range 600.00 IDR – 900.00 IDR · fair‑value band 232.37 IDR – 416.51 IDR · the 700.00 IDR price screens above the 331.96 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Famon Awal Bros Sedaya in your weekly email
Every Wednesday you see whether Famon Awal Bros Sedaya is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT Famon Awal Bros Sedaya Tbk operates a network of hospitals in Indonesia. The company offers mother and child center, heart and vascular center, trauma center, cancer center, urology center, brain and neurocenter, eye center, and sports clinic, and orthopedic center.
Show moreShow less
It also provides other health services such as clinical laboratories, homecare, and medical evacuation, as well as other healthcare services. PT Famon Awal Bros Sedaya Tbk was founded in 1997 and is based in Kemayoran, Indonesia.
Stock analysis
Famon Awal Bros Sedaya (PRAY) currently trades at 700.00 IDR, while our model-based Fair Value estimate is 331.96 IDR, 53% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 331.96 IDR per share, and 1 of the 14 models we run sit above the 700.00 IDR price.
Bear case: the Economic Profit group reads lowest at 112.96 IDR, and 13 of the 14 models stay below the price. Data coverage for this calculation is low.
Scenario range: 232.37 IDR (bear) to 416.51 IDR (bull), the price of 700.00 IDR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Famon Awal Bros Sedaya reported revenue of 2.4T IDR in FY2025 versus 1.8T IDR in FY2021, a compound +7.5%/yr. Reported net income was 211B IDR in FY2025, compounding −10.3%/yr from FY2021.
Key figures
Market cap 9.8T IDR (≈ $543M) Small · P/E ratio 52.8 · P/S ratio 3.53 · EPS (TTM) 13.25 IDR · Net margin 6.7% · Return on equity 5.5% · Return on assets (EBIT) 6.4% (5-year average) · Operating margin 8.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (low confidence).
What moves the price
The share trades about 22% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −53%, PRAY screens richer than that median.
Fair Value models
Bear232.37 IDRFair Value 331.96 IDRBull416.51 IDR
Price 700.00 IDR · Downside -52.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (11.36 IDR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.49/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+15.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.7%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−5.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.6%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.28% → 11%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks
Beats the industry median on 2/12 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside−52.6% · Bottom 25%
Profitability
Return on equity (12 months)5.5% · Below median
Return on assets3.4% · Below median
Net margin (12 months)6.7% · Above median
Operating margin (12 months)8.8% · Below median
Growth and dividend
Revenue growth (quarter YoY)35.3% · Top 25%
Balance sheet
Debt / equity0.44× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)52.8× · Priciest 25%
P/B3.02× · Pricier than median
P/S (12 months)3.53× · Priciest 25%
EV/EBITDA18.0× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 34
FUTURE (revenue growth)100· sector 31
PAST (return on equity)22· sector 32
HEALTH (low debt)78· sector 90
DIVIDEND (yield)0· sector 39
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Famon Awal Bros Sedaya Fair Value". https://www.fairvalue-calculator.com/stock/PRAY
Frequently asked questions
Is Famon Awal Bros Sedaya (PRAY) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 331.96 IDR versus a price of 700.00 IDR, about 53% lower (overvalued).
What is the fair value of PRAY?
Our model-based fair value for Famon Awal Bros Sedaya is 331.96 IDR (as of Nov 7, 2026), built from audited fundamentals. The current price: 700.00 IDR.
What is the quality score of PRAY?
Famon Awal Bros Sedaya has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Famon Awal Bros Sedaya (PRAY)?
Our model-based price target is the fair value of 331.96 IDR (as of Nov 7, 2026) from 14 valuation models. Cautious scenario 232.37 IDR, optimistic scenario 416.51 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Famon Awal Bros Sedaya stock forecast for 2026?
Our models put fair value at 331.96 IDR, about 53% lower versus a price of 700.00 IDR (overvalued). Cautious scenario 232.37 IDR, optimistic scenario 416.51 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Famon Awal Bros Sedaya (PRAY)?
Famon Awal Bros Sedaya reported trailing-twelve-month revenue of about 2.8T IDR (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of Famon Awal Bros Sedaya (PRAY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Famon Awal Bros Sedaya it is 331.96 IDR per share (as of Nov 7, 2026), against a price of 700.00 IDR. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Famon Awal Bros Sedaya stock overvalued or undervalued in 2026?
As of Nov 7, 2026, PRAY trades above its calculated fair value: price 700.00 IDR, fair value 331.96 IDR, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PRAY?
No. The price is what the market pays today (700.00 IDR); the fair value is what the company's own numbers justify (331.96 IDR). For Famon Awal Bros Sedaya the two are 368.04 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Famon Awal Bros Sedaya worth?
The market values Famon Awal Bros Sedaya at about 9.8T IDR (market capitalisation, as of Nov 7, 2026). Per share that is 700.00 IDR; our models calculate a fair value of 331.96 IDR per share.
What do the bullish and bearish scenarios say about PRAY?
Our models span a range for Famon Awal Bros Sedaya: cautious scenario 232.37 IDR, base 331.96 IDR, optimistic 416.51 IDR per share (as of Nov 7, 2026, price 700.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PRAY?
Famon Awal Bros Sedaya trades at a price-to-earnings ratio of 52.8 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 331.96 IDR is built from several models across several years. Other multiples: P/B 3.0, P/S 3.5, EV/EBITDA 18.0.
How solid is the balance sheet of Famon Awal Bros Sedaya (PRAY)?
Balance-sheet figures for Famon Awal Bros Sedaya (as of Nov 7, 2026): return on equity 5.5%, debt of 0.44 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is PRAY from its 52-week high?
Famon Awal Bros Sedaya trades at 700.00 IDR, about 22% below its 52-week high of 900.00 IDR and 16% above the low of 605.00 IDR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 331.96 IDR is for.
Which stocks are comparable to Famon Awal Bros Sedaya?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Famon Awal Bros Sedaya stock attractive at the current price?
The data as of Nov 7, 2026: price 700.00 IDR, calculated fair value 331.96 IDR (−53%), Quality Score 46/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PRAY calculated?
We run Famon Awal Bros Sedaya through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 331.96 IDR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Famon Awal Bros Sedaya itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Famon Awal Bros Sedaya (PRAY)?
The closing price on Nov 6, 2026 was 700.00 IDR. Our model-based fair value is 331.96 IDR, about 53% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Famon Awal Bros Sedaya right now?
The price sits above even our optimistic bull case (416.51 IDR). The favourable scenario is already priced in. Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Famon Awal Bros Sedaya
How large is the market capitalisation of Famon Awal Bros Sedaya (PRAY)?
The market capitalisation of Famon Awal Bros Sedaya is 9.8T IDR (≈ $543M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Famon Awal Bros Sedaya (PRAY)?
The price-to-sales ratio of Famon Awal Bros Sedaya is 3.53 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Famon Awal Bros Sedaya (PRAY)?
Earnings per share at Famon Awal Bros Sedaya are 13.25 IDR (price ÷ EPS = P/E 52.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Famon Awal Bros Sedaya (PRAY)?
The net margin of Famon Awal Bros Sedaya is 6.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Famon Awal Bros Sedaya (PRAY)?
The return on equity (ROE) of Famon Awal Bros Sedaya is 5.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Famon Awal Bros Sedaya (PRAY)?
On an EBIT basis the return on assets of Famon Awal Bros Sedaya is 6.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Famon Awal Bros Sedaya (PRAY)?
The operating margin of Famon Awal Bros Sedaya is 8.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Famon Awal Bros Sedaya (PRAY)?
Revenue at Famon Awal Bros Sedaya is growing +35.3% versus a year earlier (3y avg +17.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Famon Awal Bros Sedaya (PRAY)?
Earnings per share at Famon Awal Bros Sedaya are growing −14.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Famon Awal Bros Sedaya (PRAY) generate?
The free cash flow of Famon Awal Bros Sedaya is −403B IDR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Famon Awal Bros Sedaya (PRAY) carry?
The net debt of Famon Awal Bros Sedaya is 1.3T IDR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Famon Awal Bros Sedaya in the live analysis
One click puts Famon Awal Bros Sedaya on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026